Tumor-associated hyaluronic acid: A new sensitive and specific urine marker for bladder cancer

Cancer Research

Volumn 57, Issue 4, 1997, Pages 773-777

  Lokeshwar, Vinata B ^a   Öbek, Can ^a   Soloway, Mark S ^a   Block, Norman L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; GLYCOSAMINOGLYCAN; HYALURONIC ACID;

ANGIOGENESIS; ARTICLE; BASEMENT MEMBRANE; BLADDER CANCER; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYALURONIC ACID; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 1842417144     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics. CA Cancer J. Clin., 65: 5-27, 1996
2. Heney, N. M. Natural history of bladder cancer. Urol. Clin. North Am., 19: 429-435, 1992.
3. Soloway, M. S. The management of superficial bladder cancer. Cancer (Phila.), 45: 1856-1865, 1980.
4. Murphy, W. M. Diseases of the urinary bladder, urethra, ureters and renal pelves. In: W. M. Murphy (ed.), Urological Pathology, pp. 34-146 Philadelphia: W. B. Saunders Co., 1989.
5. Jordan, A. M., Weingarten, J., and Murphy, W. M. Transitional neoplasms of the urinary bladder: can biologic potential be predicted from histologic grading? Cancer (Phila.), 60: 2766-2774, 1987.
6. Cutler, S. J., Heney, N. M., and Friedeil, G. H. Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression. In: Bonney, W. W., and Prout, G. R. (eds.). Bladder Cancer AUA Monographs, Vol. 1, pp. 35-46, Baltimore, MD: Williams & Wilkins, 1980.
7. Heney, N. M., and Flanagan, M. J. Superficial bladder cancer progression and recurrence. J. Urol., 130: 1083-1086, 1983.
8. Hurst, R. E. Structure, function and pathology of proteoglycans and glycosaminoglycans in the urinary tract. J. Urol., 12: 3-10, 1994.
9. Nickel, J. C., and Cornish, J. Ultrastructural study of an antibody-stabilized bladder surface: a new perspective on the elusive glycosaminoglycan layer. World J. Urol., 12: 11-14, 1994.
10. Sletler-Stevenson, W. G., Aznavoorian, S., and Liotia, L. A. Tumor cell interactions with extracellular matrix during invasion and metastasis. Ann. Rev. Cell Biol., 9: 541-573, 1993.
11. McCormick, B. A., and Zetter, B. R. Adhesive interactions in angiogenesis and metastasis. Pharmacol. Ther., 53: 239-260, 1992.
12. Folkman, J. The role of angiogenesis in tumor growth. Semin. Cancer BioL, 3: 65-71, 1992.
13. Kandel, J., Bossy-Wetzel, E., and Radvani, F. Neovascularization is associated with a switch to export b-FGF in the multistep development of fibrosacroma. Cell, 66: 1095-1104, 1991.
14. West, D. C., Hampson, I. N., Arnold, F., and Kumar, S. Angiogenesis induced by degradation products of hyaluronic acid. Science (Washington DC), 228: 1324-1326, 1985.
15. Laurent, T. C., and Fraser, R. E. Hyaluronan. FASEB J., 6: 2397-2404, 1992.
16. Kmidson, W., Biswas, C., Li, X-Q., Nemec, R. E., and Toole, B. P. The role and regulation of tumor associated hyaluronan. In: J. Whelan (ed.), The Biology of Hyaluronan, Ciba Foundation Symposium 143, pp. 150-169, New York: Wiley Chichister, 1989.
17. Thomas, L., Etoh, T., Stamenkovic, S., Mihm, M. C., and Byers H. P. Migration of human melanoma cells on hyaluronate is related to CD44 expression. J. Invest. Dermatol., 100: 115-120, 1993.
18. Hobarth, K., Maier, U., and Marberger, M. Topical chemoprophylaxis of superficial bladder cancer by mitornycin C and adjuvant hyaluronidase. Eur. Urol., 21: 206-210, 1992.
19. West, D. C., and Kumar, S. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp. Cell Res., 183: 179-196, 1989.
20. Lokeshwar, V. B., Iida, N., and Bourguignon, L. Y. W. Endothelial cell adhesion molecule GP116 is a new CD44 variant (Ex14-v10) involved in mediating hyaluronic acid-induced functions. J. Biol. chem., 277: 23853-23864, 1996.
21. Banarjee, S., and Toole, B. P. Hyaluronan binding protein in endothelial cell morphogenesis. J. Cell Biol., 119: 643-652, 1992.
22. Fosang, A. J., Hey, N. J., Carney, S. L., and Hardingham, T. E. An ELISA plate based assay for hyaluronan using biotinylated proteoglycan G1 domain (HA-binding) region. Matrix, 10: 306-313, 1990.
23. Bitter, T., and Müir, H. M. A modified uronic acid carbazole reaction. Anal. Biochem., 4: 330-334, 1962.
24. Dygert, S., Li, L. H., Florida, D., and Thoma, J. A. Determination of reducing sugars with improved precision. Anal. Biochem., 13: 367-374, 1965.
25. Lokeshwar, V. B., Fregien, N., and Bourguignon, L. Y. W. Ankyrin binding domain of CD44(GP85) is required for the expression of hyaluronic acid-mediated adhesion function. J. Ceil Biol., 126: 1099-1109, 1994.
26. Lokeshwar, V. B., Huang, S. S., and Huang, J. S. Protamine induces EGF-stimulated mitogenesis by increasing cell surface EGF receptor number: implications for the existence of cryptic EGF receptor. J. Biol. Chem., 264: 19318-19326, 1989.
27. Knudson, W., Biswas, C., and Toole, B. P. Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. Proc. Natl. Acad. Sci. USA, 81: 6767-6771, 1984.
28. Lin, R. Y., Argenta, P. A., Sullivan, K. M., Stern, R., and Adzick, N. S. Urinary hyaluronic acid is a Wilms' tumor marker. J. Pediat. Surg., 30: 304-308, 1995.
29. Kumar, S., West, D. C., and Ponting, J. M. Sera of children with renal tumors contain low molecular mass hyaluronic acid. Int. J. Cancer, 44: 445-448, 1989.
30. Pham, H. T., Block, N. L., and Lokeshwar, V. B. Tumor-derived hyaluronidases: diagnostic markers for high-grade bladder cancer. Cancer Res., 57: 778-783, 1997.
31. Weiner, H. G., Vooijs, G. P., and van't Hof-Grootenboer, B. Accuracy of urine cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol., 37: 163-169, 1993.
32. Sidransky, D., and Messing, E. Molecular genetics and biochemical mechanisms in bladder cancer Urol. Clin. North Am., 19: 629-639, 1992.
33. Mao, L., Schoenberg, M. P., Scicchintano, M., Erozan, Y. S., Merlo, A., Schwab, D., and Sidransky, D. Molecular detection of detection of primary bladder cancer by mtcrosatellite DNA. 271: 659-662, 1996.
34. Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., and Folkman, J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J. Natl. Cancer Inst., 85: 241-242, 1993.
35. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., Nicholas, P. W., Skinner, D. G., Jones, P. A., and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. New Engl. J. Med., 331: 1259-1264, 1994.
36. Ho, K. J. Urinary β-glucuronidase in screening and follow up of primary urinary tract malignancy. J. Urol., 154: 1335-1338, 1995.
37. Korman, H. J., Peabody, J. O., Cerny, J. C., Yao, F. J., and Raz, A. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder. J. Urol., 154: 347-349, 1995.
38. Messing, E. M., Young, T. B., Hunt, V. B., Newton, M. A., Bran, L. L., Vaillancourt, A., Hisgen, W. J., Greenberg, E. B., Kuglitsch, M. E., and Wegenke, J. D. Hematuria home screening: repeat testing results, J. Urol., 154: 57-61, 1995.
39. Sarosdy, M. F., White, R. W., Soloway, M. S., Sheinfeld, J., Hudson, M. A., Schellhammer, P. F., Jarowenko, M. V., Adams, G., and Blumenstein, B. A. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol., 154: 379-384, 1995.
40. Soloway, M. S., Briggman, J. V., Carpinito, G. A., Chodak, G. W., Church, P. A., Lamm, D. L., Lange, P., Messing, E. M., Pasciak, R. M., Reserviez, G. B., Rukstalis, D. B., Sarosdy, M. F., Stadler, W. M., and Thiel, R. P. Use of a new tumor marker NMP22 in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol., 136: 363-367, 1996.
41. Britton, J. P., Dowell, A. C., Whelan, P., and Harris, C. M. A community study of bladder cancer screening by the detection of occult urinary bleeding. J. Urol., 148: 788-790, 1992.
42. Tengblad, A. Affinity chromatography on immobilized hyaluronate and its application to the isolation of hyaluronate binding proteins from cartilage. Biochim. Biophys. Acta, 575: 281-289, 1979.